Purpose: This study investigates the difference in whole-body dose equivalent between 6 and 15 MV image-guided radiotherapy (IGRT) for the treatment of a rhabdomyosarcoma in the prostate.
the developed models for photon and neutron dose equivalent calculation can be used for any patient geometry, tumor location, and linear accelerator. Ten percent of these second tumors are induced by the radiation treatment the patient received. 1 Most second cancers occur at the peripheral region where the dose is greater than 3.0 Gy. 1 However, Diallo et al. 2 identified a peak frequency in second malignant neoplasm (including spontaneous cancers) for volumes that received a dose smaller than 2.5 Gy. In external radiation beam therapy, the treated volume receives a high dose while the remaining body is exposed to an unwanted low dose of radiation. Usually, the dose is calculated around the target volume and the out-of-field dose is not accurately considered, if at all. 3 Therefore, whole-body dose distributions are needed for accurate cancer risk estimates and for optimizing treatment plans by minimizing the cancer risk.
Another motivation for whole-body dose calculation is the radiation protection of the fetus. Negative effects for a fetus can be substantially minimized if the dose to it is reduced to 100 mGy. 4 However, practical models to estimate the fetal exposure for intensity-modulated treatments of pregnant patients do not yet exist. 1 Takam et al. 5 presented the current status of out-of-field neutron and photon leakage dose in radiotherapy and the associated risk for the patient. Most of their results were based on patient treatments which occurred decades ago. Therefore, studies including novel treatment machines and techniques are urgently needed. 5 For the same technique applied with different nominal X-ray energies, the target coverage, conformity, and homogeneity of the treatments are similar. 6 The choice of nominal X-ray energy should be based on normal tissue complication probability and on radiation protection issues of the patient. Many studies investigated the difference in the peripheral dose between high (≥10 MV) and low nominal X-ray energy (<10 MV). [7] [8] [9] [10] [11] A Monte Carlo (MC) study conducted by Kry et al., 7 showed a similar photon out-of-field dose for 6 MV compared to 18 MV intensity-modulated radiation therapy (IMRT) treatments. For the nine organ locations investigated, the simulated neutron doses were typically much lower than the corresponding photon dose. Nevertheless, they warranted an improved neutron dosimetry in order to achieve superior estimates. Ruben et al. 8 measured the components of the out-of-field photon dose for 6 and 18 MV treatments. The neutron dose contribution was obtained from published data. They reported that X-ray energy does not affect the total photon scatter for the same treatment technique.
However, the additional neutron dose for 18 MV may have increased total body cancer risk compared to 6 MV IMRT treatments. However, they were not able to draw a firm conclusion. Hälg et al. 12 used track etch detectors to measure neutron dose equivalent in an anthropomorphic phantom for various treatment modalities. For 15 MV external photon beam treatments, the neutron dose was by factors lower compared to other literature.
With increasing number of treatments using volumetric-modulated arc therapy (VMAT) and similar dose distributions of VMAT compared to IMRT treatments, the question arises about the difference in the out-of-field dose between the two techniques. To our knowledge, there is no study published comparing the peripheral dose (including neutrons) of high-energy VMAT treatments with IMRT treatments. In the current study, the difference between the dose equivalent of 6 and 15 MV treatments was examined. It is per se not clear that for 15 MV X-ray nominal beam energy the out-of-field dose will be smaller in comparison to 18 MV because of the reduced photoneutron production. Compared to photons, neutrons are a minor part of the total out-offield dose equivalent. 1 Howell et al. 9 reported a higher effective dose for 15 MV compared to 18 MV 3D-conformal radiation therapy (3DCRT) treatments.
Also the use of X-ray imaging modalities can give a substantial dose to the patient. 13 The choice of treatment technique and indication determines the image modality and therefore, the additional amount of dose to the patient. For patient positioning, the imaging dose is justified by the reduction of the margins around the target. A smaller planning target volume will lead to a sparing of the organs at risk during irradiation. If image-guided radiotherapy (IGRT) is used, the patient receives an additional dose from X-ray imaging. By including all contributions of the whole-body dose for an IGRT treatment, a better understanding in radiation protection of the patient can be achieved.
In the current study, we investigated the whole-body dose equivalent for 6 and 15 MV IGRT treatments of a rhabdomyosarcoma in the prostate applied with three different techniques (3DCRT, IMRT, and VMAT). The analytically calculated dose distributions were verified with whole-body dose measurements. The results from the calculation were used to identify differences in the whole-body dose between the investigated treatments. Fig. 1 ). However, the radiotherapy photon and neutron dose models used in this work are generally applicable to any 3D-patient data set.
2.A.1 | Photon imaging dose
For each treatment fraction, the patient was assumed to be positioned with a full trajectory kV cone beam CT (CBCT) of the pelvis.
Hence, we assigned a relatively high imaging dose for the IGRT treatments. The mean absorbed CT dose per Alderson slice was calculated using the average of the thermoluminescence detector (TLD) dose measurements in the corresponding slice. The TLD measurements of the full trajectory pelvis CBCT are reported in Hauri et al. 14 The absorbed dose per voxel of a CBCT scan was calculated by interpolating the average CBCT dose per Alderson slab along the medial patient axis (MPAX). Hence, the dose was the same for all voxels in a transversal dose-grid slice [see Fig. 1(a) ]. According to Schneider et al., 15 the dose of a full rotation CBCT is in a first approximation homogeneous in a transversal slice.
2.A.2 | Therapy dose photons and neutrons
A previously developed photon stray dose model for static and intensity-modulated 6 MV treatments 16 was improved and adapted for 15 MV (see Appendix 1). The algorithm calculated the wholebody out-of-field dose of the coplanar treatments starting 4 cm longitudinal from the treatment volume (∼3 cm from the field edge).
According to Kry et al., 1 the differences between treatment planning system (TPS) and measurements exceed 30% of the local dose as close as 3 cm from the field edge, and differences increase by orders of magnitude at greater distances. At 4 cm longitudinal from the treatment volume, the dose of the TPS (Varian Eclipse, AAA-algorithm version 13.6.23) was fused with the model-calculated 3D outof-field dose resulting in a whole-body photon dose [see Fig. 1(b) ].
The peripheral neutron dose was calculated using an analytical model from the literature. 17 verted to a neutron dose equivalent according to Sibert and Schumacher. 18 Only the peripheral neutron dose was calculated since inside the primary X-ray beam, the dose from neutrons can be neglected when compared to the photon dose.
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2.A.3 | Whole-body dose
To obtain a typical IGRT treatment dose, a daily CBCT 3D dose was added to the 3D photon dose per session. For the 15 MV treatments, the neutron dose equivalent per session was added. The voxel-specific dose equivalents per session were multiplied with the number of sessions (see Table 1 ), resulting in the 3D dose equivalent per treatment [see Fig. 1(d) ].
2.B | Whole-body TLD measurements
The whole-body photon and peripheral neutron dose measurements served as verification of the photon stray dose and neutron dose calculation.
LiF TLD-chips (4.5 mm diameter, 0.6 mm thickness, Harshaw, Thermo Fisher Scientific, Waltham, MA, USA) were used to measure the in-and out-of-field dose of external therapy. For TLD100 (LiF:
Mg,Ti) and TLD100H (LiF:Mg,Cu,P), the same thermal treatment, calibration procedure, and readout were used as described by Hauri and Schneider. 21 The thermal treatment, calibration procedure, and
The whole-body dose equivalent for the 15 MV IMRT treatment with a daily CBCT. The dose equivalent is shown for (a) 23 times a CBCT, (b) photon scatter radiation fused with the treatment planning system calculation, (c) neutrons and (d) the summation of (a)-(c). The Fractionation scheme is presented in Table 1 . Furthermore, the outline of the rhabdomyosarcoma in the prostate can be seen.
readout for TLD600/700 (LiF:Mg,Ti) and TLD700H (LiF:Mg,Cu,P)
were the same as applied to TLD100 and TLD100H, respectively. TLD100 contains the natural abundance of 6 Li and 7 Li, while TLD600 contains primarily under-response toward lower energy (down to 0.1 MeV). 21 By building the ratio of the TLD100 and the TLD100H measured doses, the mean photon energy can be determined. Using the photon energy at a specific measurement location, the TLD correction factors for the response with radiation energy can be determined. A comprehensive description of photon dose and the mean energy measurements for the CBCT and the 6 MV treatments is given in Hauri and Schneider. 21 Furthermore, a detailed description of the uncertainties in photon dose and mean photon energy is presented.
2.B.3 | Photon dose of the 15 MV treatments
The whole-body photon dose of the 15 MV treatments was determined for 189 locations in the Alderson phantom. The detected outof-field photon dose by each TLD700H was corrected for the response with photon radiation energy. The individual correction factors were estimated by using the photon scatter contribution at each measurement location in the phantom.
The total out-of-field photon dose consists mainly of three contributions: patient scatter, collimator scatter, and head leakage. 8, 16, 24 In the middle of a 30 × 30 × 30 cm 3 water-slab phantom (source surface distance = 85 cm), the mean energy of the three scatter contributions was measured using a combination of TLD700 and TLD700H. 21 For a 10 × 10 cm 2 field (defined by the MLC), the mean energy of patient scatter was measured at 15 cm distance to the field edge. For the same field size, the mean energy of collimator scatter was determined at 15 and 35 cm distance from the field edge. At the
The total treatment dose, total MUs, and MUs per treatment Gy. The treatments were planned by an experienced worker according to a strict protocol. same locations, the mean energy of head leakage was measured for closed jaws and MLC. The separation of a field measurement into the three scatter contributions is described by Hauri et al. 16 A previously developed 6 MV out-of-field dose model 16 was improved and adapted for 15 MV (see Appendix 1) . Using the adapted model, the doses of patient scatter, collimator scatter, and head leakage were calculated for each measurement location l in the phantom. The final out-of-field mean energy E γ l;c was determined by,
with i = {patient scatter, collimator scatter, head leakage}. D As a consistency check, the TLD correction factors for the response with photon radiation energy were calculated for the 6 MV treatments (3DCRT, IMRT, and VMAT). In distinction to the 15 MV measurements, the photon energies for the 6 MV treatments were explicitly measured. 21 Using Eq. 1, the mean photon energy was calculated for each measurement location of the 6 MV treatments. The calculated and measured mean energies were converted to correction factors for the TLD100H response with photon radiation energy. The calculated and measured correction factors for the 6 MV treatments were compared to estimate the uncertainty of the TLD700H photon dose measurement.
2.B.4 | Neutron dose equivalent of the 15 MV treatments
With a combination of TLD600 and TLD700H, the whole-body neutron dose equivalent of the 15 MV treatments was determined.
TLD700H is not affected by neutrons in the energy range of interest. 25 TLD600 register photons and neutrons. Using the mean photon energy (Eq. 1), the neutron signal detected by TLD600 in the phantom was corrected for the photon contamination measured by TLD700H. The measured neutron signal of a TLD600 was transformed to neutron dose equivalent (including fast neutrons) with a depth dependent conversion factor. 17 Each TLD600-specific depth in the phantom was calculated by using a straight line connecting the X-ray producing target and the measurement location. The Alderson phantom was assumed to be a soft tissue-equivalent (ICRU), with the exception of the lungs. For the lungs, a mass density of 0.25 × ρ soft tissue was assumed (relative hydrogen content in lungs compared to soft tissue = 25% 26 ). For the 3DCRT and the IMRT treatments, the calculation of the depth in the phantom was straight-forward since there was no gantry rotation during the beam-on time. For the VMAT treatment, the control points of the one arc were grouped to six fields with different gantry angles and corresponding MUs per field. A more detailed description of the approximation of the VMAT plan by discrete fields can be found in Hauri et al. 16 Compared to the TLD600-registered signal from neutrons, the signal from photons is orders of magnitude higher in the target volume. 27 Therefore, the measurement of neutron dose equivalents was only possible outside the treatment volume.
| RESULTS
Unless otherwise stated, the mean and one standard deviation (σ)
are presented. Consistent with the IAEA report, 28 type A stands for the measured σ and the type B for the estimated σ.
3.A | Whole-body dose equivalent
3.A.1 | Photons
The deviation between the calculated whole-body dose and the 183 point-dose measurements of the CBCT scan was 0% ± 14% (type A).
The measured mean photon energies of the three stray dose contributions can be seen in Table 2 . Within the measurement uncertainties, there was no difference in the mean energies of the scatter contributions between the 15 and 6 MV field measurements.
The measured mean energy of head leakage was the same at 15 and For the 6 MV plans, the deviation between the calculated and measured correction factors for the TLD100 response with photon radiation energy was (0 ± 1) % (type A). For TLD100H, the deviation between calculated and measured correction factors was (−1 ± 1) % (type A). Using Gaussian error propagation, the uncertainty in the TLD700H dose measurement was determined to ±2% (type B) (σ = ±2% (type B) from the correction factor for the response with photon radiation energy and σ = ±1% (type A) from the raw TLD700H dose measurement 21 ).
In Fig. 3 , the different out-of-field dose contributions for a VMAT treatment can be seen. For the 6 MV treatment, patient scatter was the largest out-of-field dose contribution. For 15 MV, collimator scatter was larger compared to patient scatter. Furthermore, the CBCT reached dose levels comparable to collimator scatter.
Averaged over all 15 MV treatments (3DCRT, IMRT, and VMAT), the deviation between the calculated whole-body out-of-field photon dose and the measurement was (8 ± 10) % (type A) [Fig 2 (a) ]. For the 6 MV treatments, the deviation between calculated and measured out-of-field photon dose was (10 ± 10) % (type A). 
| DISCUSSION
Averaged over all treatment techniques and nominal X-ray energies, the calculated whole-body dose equivalent agreed within (9 ± 10) % (type A) compared to the measured dose equivalent. This agreement was sufficient to determine differences in the whole-body dose between the investigated treatments.
4.A | Photon dose
The small deviation between the predicted and measured CBCT dose justified the presented method to calculate the whole-body imaging dose.
Close to the target volume, the CBCT dose was a substantial contribution to the out-of-field dose resulting from a treatment (Fig. 5) . In the field-of-view of the CBCT, the dose was almost constant. 29 Furthermore, the field-of-view extended around 4 cm over the border of the target volume. In this area, the dose caused by scatter radiation of the primary beam dropped rapidly with increasing distance to the target volume. The CBCT dose decreased exponentially with increasing distance to the field-of-view. Hence, a smaller field-of-view is beneficial regarding radiation protection of the patient. The contribution of imaging to the total dose equivalent was similar for all investigated treatments since the number of sessions and the fraction doses were comparable for all treatments (see Table 1 ). It follows that the results obtained in this work are valid even if the imaging dose is excluded from the comparisons. A detailed discussion of the CBCT dose in context of the treatment dose can be found in the literature. 14 The mean photon energies calculated/measured outside the treatment volume were in agreement with reported out-of-field mean energies for 6 and 15 MV (static fields defined by the MLC or IMRT fields). [30] [31] [32] Kry et al. 30 simulated the same average photon energy (0.4 MeV) for a 6 MV field (defined by the MLC) as we calculated/measured in the current work. Using the simulated average mean energy, they applied an overall correction factor for TLD100
to correct the out-of-field dose measurements. However, a general correction factor leads to a systematic error in dose. 21, 31 Using the presented method to calculate the mean photon energy, this systematic error in the dose correction can be avoided.
The spectrum of patient scatter for a Simens Primus 6/15 linac was MC simulated by Chofor et al. 33 A similar photon energy of patient scatter for 6 and 15 MV beams was reported. This is in agreement with our work. Photons of lower energies have an increased probability of large Compton scatter angles compared to high-energy photons. Hence, particularly photons of lower energies from the primary X-ray spectrum cause patient scatter. The fluence ratio of low-energy photons to high-energy photons is larger for 6 MV than for 15 MV beams. This could be one of the reasons why patient scatter dose was higher for 6 MV than for 15 MV treatments.
Compared to the primary beam, the X-ray spectrum in the peripheral region is softer such that an increase in organ-specific relative biological effectiveness (RBE) for carcinogenesis is expected. 34 With the presented method, the dose and corresponding mean photon energy can be calculated separately for patient scatter, collimator scatter, and head leakage. Hence, for every scatter contribution, a separate RBE for cancer induction can be determined.
Close to the field edge, where patient scatter and collimator scatter dominated (see Fig. 2 ), the 6 MV treatments showed a higher dose than the 15 MV counterparts. This is in agreement with a MC study from the literature. 35 For a standard field, patient scatter was increased by a factor of two for 6 MV compared to 15 MV (Fig. 8) , whereas collimator scatter was reduced just by a factor of 1.5 for 6 MV compared to 15 MV (Fig. 9 ). This factor was reduced further because collimator scatter scales with the applied MUs 16 and the 6 MV treatments needed more MUs compared to the 15 MV treatments (Table 1) .
Ruben et al. 8, 24 measured the components of the out-of-field dose for IMRT and 3DCRT fields up to a distance 40 cm from the isocenter. In agreement with our work, they reported a decreasing patient scatter dose for increasing nominal X-ray energy. Furthermore, they measured nearly the same 3DCRT out-of-field dose for 6 and 15 MV treatments. In their study, both 3DCRT treatments utilized the same MUs. We noticed an overall lower photon dose with the 15 MV than with the 6 MV 3DCRT treatment. In our study, lesser
MUs were needed to apply the 15 MV than the 6 MV treatments.
The improved general model for stray dose calculation 16 predicted the measured off-axis photon dose contribution in the anthropomorphic phantom well. To our knowledge, this is the only analytical model for whole-body photon dose prediction for static and intensity-modulated treatments. An analytical model to calculate the out-of-field dose for intensity-modulated treatments was introduced by Sanchez et al. 32 Their model is only applicable for distances ≥10 cm from the field edge because they neglected the patient scatter contribution. However, close to the field edge, the largest out-of-field dose gradients are present. Furthermore, the TPS cannot be used to calculate the out-of-field dose up to 10 cm from the field edge since differences between TPS and measurements exceed 30% of the local dose as close as 3 cm from the field edge, 1 and differences increase by orders of magnitude at greater distances.
An aspect of neutron interaction in the phantom is the production of capture gamma-ray emission. The dose contribution from this emission can be neglected for photon radiotherapy since it is small compared to the scatter photon dose of the primary beam. 19 However, using TLD700H the capture gamma rays were measured together with the scatter photon dose. Furthermore, the capture gamma-ray contribution was included in the predicted head leakage dose since the scatter dose model was adjusted using ionization 
4.C | Total dose equivalent
The DEVHs of the calculated photon stray dose were in good agreement with the DEVHs of the measurement (Fig. 5) . Hence, the measurement locations represented a whole-body photon dose well. In comparison, DEVH of the calculated neutron dose equivalents showed more dose per volume than the DEVHs from the measurements. This can be explained by the fact that most of the TLD measurement locations were deeper than 1 cm in the phantom. 20 The locations were chosen such that they cover all ICRP-recommended organs. 37 The neutron dose decreases rapidly with increasing depth in the phantom [ Fig. 1(a) ]. In terms of radiation protection, the high neutron dose contribution down to 1 cm in the patient is of less importance since most ICRP organs are located deeper in the body. and are in a first approximation independent of the field shape. 1 The relative difference in MUs for the 6 MV compared to the 15 MV treatment was smaller for the intensity-modulated treatments when compared to the 3DCRT treatments (see Table 1 ). This explained the crossing of the 6 and 15 MV DEVHs for the intensity-modulated treatments at 0.2 Sv (see Fig. 5c ). For the 3DCRT treatments, the DEVH of the 15 MV plan was equal or below the 6 MV DEVH.
Hence, regarding radiation protection of the patient, the 3DCRT
15 MV treatment was superior compared to the 6 MV treatment.
Head leakage and neutron DEVHs can be seen in Fig. 7 .
Head leakage was almost constant in the phantom, whereas neutron dose was inhomogeneous. For all techniques, the minimum dose was higher for 6 MV than for 15 MV. This was caused by a smaller leakage dose for 15 MV than for 6 MV (Fig. 9) and the low neutron dose in the center of the body [ Fig. 1 (c) ]. Head leakage is assumed to be reduced because of more forward-directed photons in the X-ray producing target for 15 MV than for 6 MV. Primus). 40 Hence, regarding radiation protection of the patient for high-energy treatments, the choice of treatment machine should not only be based on neutron production but rather on the total dose equivalent including photon scatter.
Multiple studies reported an increased cancer risk based on an increased dose equivalent for high energy compared to low-energy radiotherapy. 35, 39 The increased dose equivalent for high compared to low-energy X-ray therapy was reported to be caused by the additional neutron dose. However, the neutron energies in these publications were overestimated resulting in an overestimation of neutron dose. An extensive discussion of the overestimation in neutron dose reported by the literature can be found in Kry et al. 7 For the same treatment technique, we did not notice an increase in the whole-body dose equivalent for increasing nominal X-ray energy (up to 15 MV). For IMRT treatments, the findings are in agreement with an MC study made by Kry et al. 7 They found that, the calculated 6 and 18 MV out-of-field doses were similar for IMRT.
A shortcoming of this study is that the investigation was focused only to one treatment location (rhabdomyosarcoma in the prostate).
In addition, the whole-body doses were calculated using an anthropomorphic phantom and not a patient CT. This had the advantage that the calculation could be directly compared to the measurements. Nevertheless, the dose models used in this manuscript are applicable to other treatment locations and patient geometries. The photon dose calculated using the stray dose model 16 was in good agreement (absolute mean deviation of 22%) with whole-body dose measurements of 6 MV treatments for Hodgkin disease (involved field and involved node), and for treatments of an ependymoma in the head (3DCRT, IMRT, and VMAT). 41 Regarding out-of-field dose,
Head leakage (hl) and neutron (n) DEVH for (a) the IMRT and (b) the 3DCRT treatments.
further investigations are planned for different treatment indications.
These investigations are urgently needed. 5 The calculated CBCT dose distribution was based on whole-body measurement. It is time consuming and not practical to measure the dose of various CBCT protocols. Furthermore, the choice of the protocol influences the dose distribution in the field-of-view region. 29 Analytical models to calculate the CBCT dose are available but they lack the ability to calculate the dose outside the field-of-view. 42 We did not include the out-of-field dose caused by electron contamination. Outside the primary beam, the dose close to the surface can be increased by a factor of 4 compared to inside the body (>2 cm). 10 However, most critical organs are located in a patient depth outside the reach of these electrons. Furthermore, usually treatments are applied using multiple gantry angles, which reduces the increased surface dose caused by electron contamination com- For the calculation of the total whole-body dose of a real patient, the planning CT can be fused with a phantom containing the contours of critical tissues. 43 Such a feature is not yet clinically available.
Using the application programming interface of the Eclipse TPS, it is planned to fuse the limited patient CT with a computational human phantom from a library to generate a whole-body representation of the patient.
| CONCLUSION
The calculated whole-body dose equivalent for IGRT treatments helped Second cancer risk estimations are limited by the errors in the risk model and the whole-body dose calculation. In this work, the accuracy and precision of the dose estimation were improved. Further research should be carried out to improve cancer risk models and whole-body dose calculations to achieve better estimates in second cancer induction.
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APPENDIX 1 6 MV AND 15 MV PHOTON SCATTER MODELS
A general model for photon stray dose calculation developed for a
TrueBeam operated at nominal X-ray energy of 6 MV 16 was improved and adjusted for 15 MV. The total absorbed dose outside the treatment field D t can be described as the sum of three contributions, 
Patient scatter model
The four parameters of the mechanistic model of patient scatter see [Eq. (8) from Hauri et al. 16 ] were adapted for 15 MV nominal X-ray energy. The total absorbed dose was measured in simple geometries using a Rigid Stem ionization chamber 30016 (PTW, Freiburg, Germany). Patient scatter was extracted from the total out-of-field measurement and the four physically motivated fit parameters were determined. In Table 3 , the evaluated parameters for 15 MV nominal X-ray energy can be seen. In Fig. 8 , we see the comparison between patient scatter resulting from 15 to 6 MV nominal X-ray energy. The normalized patient scatter as a function of field widths and lengths showed no difference between 15 and 6 MV [ Fig. 8(a) ]. The absolute patient scatter dose 15 cm from the field edge along a line parallel to the central field axis (R-dependence 16 ) showed a higher dose for 6 MV than for 15 MV [ Fig. 8(b) ].
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For 6 MV, Chofor et al. 33 simulated an almost twofold increase in patient scatter compared to 15 MV. Ruben et al. 8 measured a 1/3 higher patient scatter dose for 6 MV than for 18 MV. However, the difference in patient scatter between two nominal X-ray energies is dependent on the location in the patient, as can be seen in Fig. 8(b) . Patient scatter is independent from the beam head design and is an unavoidable result of external radiotherapy. 33 Table III shows that primarily the normalization constant of the patient scatter model has to be adjusted when using different beam energies. The normalization constant can be determined by one measurement set-up. However, for flattening filter free beams, all model parameters could be different compared to flattening filter beams.
Collimator scatter and head leakage models
The empirical models of collimator scatter and head leakage 16 With the results, a scaling matrix was calculated which corrected for the change of collimator scatter with changing MLC width opening. No such effect was noticed for a variation in the MLC length opening. 16 To calculate collimator scatter and head leakage for a treatment, the dose contributions along the MPAX were scaled with the exponential decrease in depth. To determine the depth, the patient was assumed to be water equivalent with the exception of the lungs (ρ lungs = 0.25 × ρ water ). A more detailed description how the depth in the patient was calculated for each treatment field can be found in
Hauri et al. 16 In Fig. 9 , we see collimator scatter and head leakage per Along the MPAX, head leakage for 6 MV was around 1.6 times higher than head leakage for 15 MV. For both nominal X-ray energies, head leakage showed the same increase for increasing distance to the isocenter. A possible explanation could be the change in photon attenuation for different paths through the gantry head's shielding.
In Table 4 , we see the measured attenuation coefficient for collimator scatter and head leakage. In contrast to the expectation, the attenuation of the scatter contribution was higher for 15 MV than for 6 MV. The attenuation for collimator scatter was calculated using a straight line connecting the rear jaw and the point of interest in the patient. For head leakage, the attenuation was calculated using a straight line connecting the X-ray producing target with the point of interest located in the patient.
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